Understanding Causes of Death in Patients With Acute Respiratory Distress Syndrome: A Narrative Review.

Objectives: To provide a comprehensive summary of the published data on cause of death in patients with acute respiratory distress syndrome (ARDS).

Data Sources: PubMed (January 2015 to April 2024), bibliographies of relevant articles, and ARDS Network and Prevention & Early Treatment of Acute Lung Injury (PETAL) network websites.

Study Selection: Observational studies and clinical trials that reported on cause of death in greater than or equal to 30 patients with ARDS, not obtained from death certificates.

An empirically generated responder definition for rosacea treatment.

Objective: The aim of this study was to empirically generate a responder definition for the treatment of papulopustular rosacea.

Methods: A total of 8 multicenter clinical studies on patients with papulopustular facial rosacea were analyzed. All patients were treated with azelaic acid and/or comparator treatments.

Comparison of Occlusive and Open Application in a Psoriasis Plaque Test Design, Exemplarily Using Investigations of Mapracorat 0.1% Ointment versus Vehicle and Reference Drugs.

Background/aims: Psoriasis plaque tests (PPTs) are important tools in the early phases of antipsoriatic drug development. Two distinct PPT design variants (open vs. occluded drug application) are commonly used, but no previous work has aimed to directly compare and contrast their performance.

Patient-reported outcomes of azelaic acid foam 15% for patients with papulopustular rosacea: secondary efficacy results from a randomized, controlled, double-blind, phase 3 trial.

Patient-reported treatment outcomes are important for evaluating the impact of drug therapies on patient experience. A randomized, double-blind, vehicle-controlled, parallel-group, multicenter, phase 3 study was conducted in 961 participants to assess patient perception of efficacy, utility, and effect on quality of life (QOL) of an azelaic acid (AzA) 15% foam formulation for the treatment of papulopustular rosacea (PPR). Secondary end points included patient-reported global assessment of treatment response, global assessment of tolerability, and opinion on cosmetic acceptability and practicability of product use.

Investigator-reported efficacy of azelaic acid foam 15% in patients with papulopustular rosacea: secondary efficacy outcomes from a randomized, controlled, double-blind, phase 3 trial.

Papulopustular rosacea (PPR) is characterized by centrofacial papules and pustules commonly associated with erythema. To compare investigator-reported efficacy outcomes for azelaic acid (AzA) foam 15% versus vehicle foam in PPR, a randomized, vehicle-controlled, double-blind phase 3 clinical trial was conducted at 48 US sites. Participants received AzA foam or vehicle foam for 12 weeks.

A phase 3 randomized, double-blind, vehicle-controlled trial of azelaic acid foam 15% in the treatment of papulopustular rosacea.

Rosacea is a chronic relapsing skin disorder primarily affecting the face. Although its etiology is not well defined, rosacea is associated with immune dysregulation and inflammation potentiated by external factors. These manifestations lead to skin sensitivity and impaired quality of life.

[Psoriasis--clinical picture and current therapy].

This review describes the current knowledge level of epidemiology, genetics and pathogenesis of psoriasis for continuing education purposes. The different clinical appearances and degrees of severity of the illness are portrayed and important associated diseases are depicted. Treatment goals are designated and different therapy forms like topical therapy, phototherapy and classical as well as modem systemic therapies (biologicals) are described.

Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis.

Glatiramer acetate (copolymer 1, Copaxone) is a mixture of synthetic polypeptides and is used for the treatment of multiple sclerosis. It has been shown to possess beneficial effects in reducing the relapse rate in relapsing-remitting multiple sclerosis. Its main mechanism of action is regarded as a switch of the immune reaction from a T helper (Th)1 to a Th2 cell type.